Stimwave today responded to a patent infringement suit filed by Nevro (NYSE:NVRO) stating that the claims made against the company are “completely baseless, unfounded and invalid.”
In its suit, which was filed in the U.S. District Court for the District of Delaware last week, Nevro claims that Pompano Beach, Fla.-based StimWave infringed on patents related to Nevro’s Senza system and HF10 therapy.
Nevro is seeking preliminary and permanent injunctive relief against further infringement as well as damages and attorney’s fees, Redwood City, Calif.-based Nevro said.
“Stimwave has never practiced the methods or art stated in any Nevro patent. Receivers and signal delivery devices have been utilizing kHz frequency ranges for over 40 years. We plan to rigorously respond to this action and proceed with a motion to dismiss in the coming months as well as evaluate separate actions,” Stimwave CEO Laura Tyler Perryman said in a press release.
Last month, Stimwave touted six-month data from a trial of its minimally invasive spinal cord stimulator system.
